|本期目录/Table of Contents|

[1]郝瑞敏,申戈,李丹,等.立体定向放疗治疗胰腺癌临床观察[J].慢性病学杂志,2015,(04):378-381.
　HAO Rui-min,SHEN Ge,LI Dan,et al.Stereotactic body radiotherapy in the treatment of pancreatic cancer[J].,2015,(04):378-381.
点击复制

立体定向放疗治疗胰腺癌临床观察(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2015年04期
页码:
378-381
栏目:
论著
出版日期:
2015-08-30

文章信息/Info

Title:
Stereotactic body radiotherapy in the treatment of pancreatic cancer
作者:
郝瑞敏; 申戈; 李丹; 周明; 孙慧茹; 杨刚; 董大鹏; 薛俊霞; 黄州; 吴世凯
解放军307医院放疗科，北京100071
Author(s):
HAO Rui-min;  SHEN Ge;  LI Dan; ZHOU Ming;  SUN Hui-ru;  YANG Gang;  DONG Da-peng;  XUE Jun-xia;  HUANG Zhou; WU Shi-kai
Departmentof RadiationOncology,307HospitalofPLA,Beijing100071,China Correspondingauthor:SHENGe,E-mail:shenge219@126.com
关键词:
胰腺肿瘤; 射波刀; 局部控制率; 生存时间
Keywords:
Pancreatic cancer;  Cyberknife;  Local control;  Overall survival
分类号:
R735.9
DOI:
-
摘要:
目的 分析立体定向放疗治疗胰腺癌的局控率与患者生存时间。方法 2012年1月17日至2015年1 月28日采用射波刀治疗的胰腺癌患者25例，70%剂量线覆盖100%计划靶区（PTV），总剂量25~35 Gy/5f。 结果 近期疗效部分缓解（PR）16%(4/25)，稳定（SD）80%(20/25)，进展（PD）4%(1/25)；症状缓解率 72%（18/25）。所有患者射波刀治疗后中位生存时间15个月，6个月生存率84%（21/25），1年生存率 48%（12/25），2年生存率16%（4/25）。2级消化道反应20%(5/25)，2级白细胞减少1例，未见其他不良 反应。结论 射波刀治疗可以提高患者的总生存时间以及肿瘤局部控制率，毒性耐受良好。
Abstract:
Objective To explore the local control and survival rate of pancreatic cancer patients treated with stereotactic body radiation therapy (SBRT).Methods From January 17, 2012 to January 28, 2015, a total of 25 pancreatic cancer patients were treated with Cyberknife. The total radiation dose was25-35 Gy, which corresponded to5.0-7.0 Gy per fraction (70% isodose line) and5 fractions. Results The partial response (PR) rate, stable disease (SD) rate and progression disease (PD) was 16%,80% and4%, respectively. The remission rate was72%. The6-month,1-year and2-year sur-vival rate were 84%,48% and16%, respectively. The acute radiation reactions were mostly gastrointes-tinal reactions (20%). Only one patient had grade-2leukopenia, with no other adverse reactions. Conclu-sionsThe Cybernife radiotherapy is a safe and effective treatment for pancreatic cancers. The better lo-cal control rate and long-term survival rate are as expected.

参考文献/References:

[1] FerlayJ,ShinHR,BrayF,et al.Estimatesofworldwideburden ofcancer in 2008: GLOBOCAN 2008[J]．Int J Cancer, 2010,127(12):2893-2917.
[2] 陈可欣,张思维,李连弟.中国胰腺癌死亡情况报告[J]．中华 流行病学杂志,2003,24:520-522.
[3] Goldstein D, Carroll S, Apte M,et al. Modern management of pancreatic carcinoma[J]．Intern Med J,2004,34(8):475-481.
[4] Waner M, Redaelli C, Lietz M,et al. Curative resection is the single most important factor determining outcome in patients with pancreatie adenocarcinoma[J]．Br J Surg,2004,91(5): 586-594.
[5] Willett CG, Czito BG, Bendell JC,et al. Locally advanced pancreatic cancer[J]．J Clin Oncol,2005,23(20):4538-4544.
[6] Nishimura Y, Hosotani R, Shibanoto Y,et al. External and intraoperative radiotherapy for reseetable and unresectable pan?creatic cancer: analysis of survival rates and complications[J]． In J RadiatOncolBiolPhys,1997,39(1):39-49.
[7]Shibamoto Y, Manabe T, Ohshio G,etal.High-dose intraop? erative radiotherapy for unresectable pancreatic cancer[J]． IntJ RdiatOncolBiolPhys,1996,34(1):57-63.
[8]Heinemann V, Boeck S, Hinke A,et al. Meta analysis of ran? domized trials: Evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic can? cer[J]．BMC Cancer,2008,8:82.
[9]Kharofa J, Kelly TR, Ritch PS,et al. 5-FU/leucovorin, iri? notecan, oxaliplatin (FOLFIRINOX) induction followed by chemoXRT in borderline resectable pancreatic cancer [J]． ASCO MeetAbstr,2012,30(15Suppl)):e14613.
[10]Gunturu KS, Yao X, Cong X,et al. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity[J]．Med Oncol, 2013,30(1):361.
[11]Moore MJ, Goldstein D, Hamm J,et al. Erlotinib plus gem? citabine compared with gemcitabine alone in patients with ad? vanced pancreatic cancer: a phase III trial of the national cancer institute of Canada clinical trials group [J]．J Clin Oncol, 2007,25(15):1960–1966.
[12]于金明,于甬华,尹勇,等.X射线立体定向放射治疗胰头癌13例 分析[J]．中华放射肿瘤学杂志,2001,10(2):125.
[13]Wang J, Xia TY, Wang YJ,et al. Long-term results of gam ma ray-based stereotacitc body radiation therapy in treatment of medically unfit or inoperable non-metastatic pancreatic ade nocarcinoma[J]．Int J Radiat Oncol Biol Phys, 2012,84: s815-816.
[14]Gorovets D, Saif MW, Huber K,et al. Novel treatment ap? proaches for locally advanced pancreatic cancer[J]．JOP, 2014,15(2):95-98.
[15]Pollom EL, Alagappan M, Chan C,et al. Outcomes and tox? icity of SBRT for patients with unresectable pancreatic adeno? carcinoma[J]．J Clin Oncol,2014,32(Suppl3):317.
[16]Moningi S, Raman SP, Dholakia AS,et al. Stereotactic body radiation therapy for pancreatic cancer: single institutional expe? rience[J]．J Clin Oncol,2014,32(Suppl3):328.
[17]Gurka MK, Kim CM, Haddad NG,et al. Stereotactic body ra? diation therapy (SBRT) combined with chemotherapy for local? ly advanced pancreatic adenocarcinoma [J]．J Clin Oncol, 2014,32(Suppl3):361.

备注/Memo

备注/Memo:
作者简介：郝瑞敏，硕士，主治医师，主要从事肿瘤放疗 工作 通信作者：申戈，E-mail: shenge219@126.com
更新日期/Last Update: 2015-08-25